Clinical Use of Insulin Glargine 300 U/mL in Adults with Type 2 Diabetes : Hypothetical Case Studies

Show full item record



Permalink

http://hdl.handle.net/10138/343688

Citation

Harris , S B , Parente , E B & Karalliedde , J 2022 , ' Clinical Use of Insulin Glargine 300 U/mL in Adults with Type 2 Diabetes : Hypothetical Case Studies ' , Diabetes therapy , vol. 13 , no. 5 , pp. 913-930 . https://doi.org/10.1007/s13300-022-01247-7

Title: Clinical Use of Insulin Glargine 300 U/mL in Adults with Type 2 Diabetes : Hypothetical Case Studies
Author: Harris, Stewart B.; Parente, Erika B.; Karalliedde, Janaka
Contributor organization: CAMM - Research Program for Clinical and Molecular Metabolism
University of Helsinki
Nefrologian yksikkö
Date: 2022-05
Language: eng
Number of pages: 18
Belongs to series: Diabetes therapy
ISSN: 1869-6953
DOI: https://doi.org/10.1007/s13300-022-01247-7
URI: http://hdl.handle.net/10138/343688
Abstract: Type 2 diabetes (T2D) is a progressive disease, with many individuals eventually requiring basal insulin therapy to maintain glycaemic control. However, there exists considerable therapeutic inertia to the prompt initiation and optimal titration of basal insulin therapy due to barriers that include fear of injections, hypoglycaemia, weight gain, and burdensome regimens. Hypoglycaemia is thought to be a major barrier to optimal glycaemic control and is associated with significant morbidity and mortality. Newer second-generation basal insulin analogues provide comparable glycaemic control with lower risk of hypoglycaemia compared with first-generation basal insulin analogues. The present review article discusses clinical evidence for one such second-generation basal insulin analogue, insulin glargine 300 U/mL (Gla-300), in the context of hypothetical case studies that are representative of individuals who may attend routine clinical practice. These case studies discuss individualised treatment needs for people with T2D who are insulin-naive or pre-treated. Clinical characteristics such as older age, frequent nocturnal hypoglycaemia, and renal impairment, which are known risk factors for hypoglycaemia, are also considered.
Subject: Basal insulin analogues
Glycaemic control
Hypoglycaemia
Insulin glargine 300 U
mL
Type 2 diabetes
GLYCEMIC CONTROL
BASAL INSULIN
SEVERE HYPOGLYCEMIA
ELDERLY-PATIENTS
GLUCOSE CONTROL
100 UNITS/ML
PEOPLE
TRIAL
OUTCOMES
PATHOPHYSIOLOGY
3121 General medicine, internal medicine and other clinical medicine
Peer reviewed: Yes
Rights: cc_by_nc
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
Harris2022_Arti ... UseOfInsulinGlargine30.pdf 851.9Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record